<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) are recognized to predispose to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Abdel-Latif and colleagues recently suggested that esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> might be resistant to multimodality treatment </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigated potential differences in clinical outcomes in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> patients based on the presence of identifiable Barrett's mucosa and/or history of symptomatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Eighty-four patients with resectable esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, who completed the planned preoperative <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> and underwent a potentially curative esophageal resection were retrospectively evaluated </plain></SENT>
<SENT sid="4" pm="."><plain>Postoperative survival was compared between patients with or without underlying <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and history of symptomatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with pathologic complete response (path CR) and those with partial or no response (path PR) were compared to determine if presence of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and history of symptomatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> influence the path CR rates </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: We found significantly lower postoperative survival in patients with Barrett's associated <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (vs <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> arising de novo, p = 0.031) and patients with symptomatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> (vs patients without symptomatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, p = 0.019) </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, the subset of patients with path PR (vs path CR) after <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> have a significantly higher proportion of patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (HR = 4.38, confidence interval [CI] = 1.39 to 13.83, p = 0.012) and patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> (HR = 2.71, CI = 1.13 to 6.50, p = 0.026) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Patients with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> may have differences in response to preoperative <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> based on the presence of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and history of symptomatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
</text></document>